BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30221329)

  • 1. Correction to: a risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score.
    Yhim HY; Park Y; Han YH; Kim S; Kang SR; Moon JH; Jeong JH; Shin HJ; Kim K; Choi YS; Kim K; Kim MK; Kong E; Kim DS; Eo JS; Lee JH; Kang DY; Lee WS; Lee SM; Do YR; Ham JS; Kim SJ; Kim WS; Choi JY; Yang DH; Kwak JY
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2482-2483. PubMed ID: 30221329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score.
    Yhim HY; Park Y; Han YH; Kim S; Kang SR; Moon JH; Jeong JH; Shin HJ; Kim K; Choi YS; Kim K; Kim MK; Kong E; Kim DS; Eo JS; Lee JH; Kang DY; Lee WS; Lee SM; Do YR; Ham JS; Kim SJ; Kim WS; Choi JY; Yang DH; Kwak JY
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2274-2284. PubMed ID: 30056546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index.
    Yim SK; Yhim HY; Han YH; Jeon SY; Lee NR; Song EK; Jeong HJ; Kim HS; Kwak JY
    Ann Hematol; 2019 Dec; 98(12):2739-2748. PubMed ID: 31712879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT-based versus FDG-PET/CT-based NCCN international prognostic index risk stratification in DLBCL.
    Adams HJ; de Klerk JM; Fijnheer R; Dubois SV; Nievelstein RA; Kwee TC
    J Natl Compr Canc Netw; 2015 Feb; 13(2):171-6. PubMed ID: 25691609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ukraine Data on Prognostic Factors and Treatment Outcomes in Patients with Peripheral T-Cell Lymphomas.
    Skrypets T; Novosad O; Pastushenko Y; Gorbach O; Kriachok I
    Klin Onkol; 2019; 32(6):436-444. PubMed ID: 31842562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
    Coutinho R; Lobato J; Esteves S; Cabeçadas J; Gomes da Silva M
    Ann Hematol; 2019 Aug; 98(8):1937-1946. PubMed ID: 30949752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
    Melchardt T; Troppan K; Weiss L; Hufnagl C; Neureiter D; Tränkenschuh W; Hopfinger G; Magnes T; Deutsch A; Neumeister P; Hackl H; Greil R; Pichler M; Egle A
    Br J Haematol; 2015 Jan; 168(2):239-45. PubMed ID: 25236324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
    Sonnen R; Schmidt WP; Müller-Hermelink HK; Schmitz N
    Br J Haematol; 2005 May; 129(3):366-72. PubMed ID: 15842660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.
    Hong J; Kim SJ; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Lee HS; Yun HJ; Lee SI; Kim MK; Yi JH; Lee JH; Kim WS; Suh C
    Oncotarget; 2017 Nov; 8(54):92171-92182. PubMed ID: 29190906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
    Zhang XY; Song L; Wang PJ; Wang L; Li Y; Wang YY; Shi CL
    Acta Haematol; 2020; 143(2):124-130. PubMed ID: 31382264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Immune Microenvironmental Factors for Improving the IPI-related Risk Stratification of Aggressive B Cell Lymphoma.
    Gong Y; Chen R; Zhang X; Zou ZM; Chen XH
    Biomed Environ Sci; 2017 Jul; 30(7):492-500. PubMed ID: 28756808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β
    Montalbán C; Díaz-López A; Dlouhy I; Rovira J; Lopez-Guillermo A; Alonso S; Martín A; Sancho JM; García O; Sánchez JM; Rodríguez M; Novelli S; Salar A; Gutiérrez A; Rodríguez-Salazar MJ; Bastos M; Domínguez JF; Fernández R; Gonzalez de Villambrosia S; Queizan JA; Córdoba R; de Oña R; López-Hernandez A; Freue JM; Garrote H; López L; Martin-Moreno AM; Rodriguez J; Abraira V; García JF;
    Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
    Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
    Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.
    Milgrom SA; Dong W; Akhtari M; Smith GL; Pinnix CC; Mawlawi O; Rohren E; Garg N; Chuang H; Yehia ZA; Reddy JP; Gunther JR; Khoury JD; Suki T; Osborne EM; Oki Y; Fanale M; Dabaja BS
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):333-338. PubMed ID: 28068241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction to: ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.
    Nishimi A; Isozaki T; Nishimi S; Ishii S; Tokunaga T; Furuya H; Wakabayashi K; Kasama T
    Clin Rheumatol; 2018 Apr; 37(4):1025-1026. PubMed ID: 29525842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction to: Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.
    Pöyhönen L; Bustamante J; Casanova JL; Jouanguy E; Zhang Q
    J Clin Immunol; 2019 Jul; 39(5):527. PubMed ID: 31175480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.